Advancing First-Line Treatment Strategies in Gastric and Esophageal Cancers
Panelists discuss how the 5-year survival data for nivolumab plus chemotherapy underscore its sustained efficacy as a first-line treatment, showing durable benefits over alternatives. Further research, including real-world evidence and broader clinical trials, is needed to validate its long-term impact across diverse patient populations and cancer subtypes.
- What insights do the 5-year survival data for nivolumab plus chemotherapy provide when considering its efficacy alongside other first-line treatments for these cancers?
- What additional research or real-world evidence might be needed to further solidify the role of nivolumab plus chemotherapy based on these findings?
Recent Videos
Related Content
FDA Approves Pembrolizumab/Chemo in First-Line Gastric/GEJ Adenocarcinoma
March 19th 2025Article
Data from the phase 3 KEYNOTE-811 trial supported the FDA approval of this pembrolizumab combination in locally advanced unresectable or metastatic, PD-L1–positive, HER2-positive gastric or GEJ adenocarcinoma.
